Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AdvaMed Seeking To Lower New Tech Payment Threshold In House Rx Bill

This article was originally published in The Gray Sheet

Executive Summary

Authorization of $1.6 bil. in additional funding for new tech "add-on" payments in House Medicare reform legislation represents a move by lawmakers to alleviate hospital concerns with the original new technology provisions

You may also be interested in...



Medicare Reform Bills Head To Conference; Competitive Bidding Fuels Debate

AdvaMed will work closely with Sens. Rick Santorum (R-Penn.) and Blanche Lincoln (D-Ark.) to ensure language easing criteria for new technology "add-on" payments is included in the final Medicare bill

Medicare Reform Bills Head To Conference; Competitive Bidding Fuels Debate

AdvaMed will work closely with Sens. Rick Santorum (R-Penn.) and Blanche Lincoln (D-Ark.) to ensure language easing criteria for new technology "add-on" payments is included in the final Medicare bill

MedPAC Recommends Methods To Ease Transition To Competitive Bidding

Inclusion of a mandatory trial period in a competitive bidding program that allows Medicare beneficiaries to switch to a non-winning supplier if dissatisfied with the program's quality may be a way to gain beneficiary support for competitive bidding, according to MedPAC's 1June report

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel